ABIONYX Pharma Announces Its Financial Agenda for the Year 2022
31 Janvier 2022 - 05:45PM
Business Wire
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
today announces its financial agenda for 2022.
Events
Date*
Cash position and activity update for
Q4 2021
February 24, 2022
2021 Annual Results
April 28, 2022
Cash position and activity update for
Q1 2022
May 19, 2022
Cash position and activity update for
Q2 2022
August 18, 2022
2022 Half Year Results
September 29, 2022
Cash position and activity update for
Q3 2022
November 17, 2022
* indicative dates subject to change
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220131005656/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024